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Testicular neoplasms are comprised of a variety of histologically different forms, and their pathogenesis has not been elucidated.
Dysadherin is a recently described cell membrane glycoprotein, which has an anticell–cell adhesion function and downregulates
E-cadherin. In this study, we examined immunohistochemically the expression of E-cadherin and dysadherin in 120 testicular
neoplasms (37 seminomas-26 classic, five spermatocytic and six anaplastic-, 45 embryonal carcinomas, 10 mixed germ cell tumours,
two yolk sac tumours, 10 mature and eight immature teratomas and eight non-Hodgkin B-cell lymphomas), clinical stage I. The
intensity, the expression pattern and the percentage of neoplastic cell staining was recorded and correlated with the histologic type
and vascular/lymphatic invasion. Dysadherin was not expressed in non-neoplastic germ cells, neither in CIS/ITGCNU, but it was highly
expressed in all types of germ cell tumours, that demonstrated either embryonic phenotype or somatic differentiation, in most
terminally differentiated neoplasms, and in all lymphomas. Dysadherin expression did not correlate with vascular invasion. Increased
dysadherin expression was correlated with aberrant E-cadherin expression in most tumours. In 17% of embryonal carcinomas
colocalisation of dysadherin and membranous E-cadherin staining was noted. This is the first report on dysadherin expression and its
association with E-cadherin in testicular tumours. Since dysadherin is not normally expressed in non-neoplastic testis, it is conceivable
that it plays a role in the neoplastic transformation of germ cells. In testicular tumours, as in other neoplasms, dysadherin
downregulates E-cadherin expression, at least in part.
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Testicular germ cell tumours (TGCTs) are the most common
malignancy in young males, with peak incidence between 20 and
40 years of age (Adami et al, 1994). They arise from the germinal
epithelium of the seminiferous tubules and are comprised by many
histologically different types. Based on their presumed histogenesis
and their line of differentiation, a practical classification system
for clinical purposes has been adopted (Mostofi and Sobin, 1997;
Rosai, 2004). Thus, they are divided into two major categories:
seminomas and nonseminomatous germ cell tumours (NSGCTs).
According to the WHO classification in the first category belong
the classic seminoma, the spermatocytic seminoma and also
anaplastic seminomas. In the latter, the major types are the
embryonal carcinoma, yolk sac tumour, choriocarcinoma, and
teratomas (mature and immature). There are also mixed germ cell
tumours that are comprised of various percentages of both
seminomas and NSGCTs. It is believed that both seminomas and
NSGCTs originate from a common precursor, carcinoma in situ/
intratubular germ cell neoplasia unclassified (CIS/ITGCNU).
Testicular non-Hodgkin lymphoma is an uncommon neoplasm
that affects mostly elderly men, accounting for 25–50% of the
testicular tumours in men above 50 years of age. The pathogenesis
of both TGCTs and testicular lymphomas remains poorly under-
stood.
The cadherin family is a group of Ca
2þ-dependent cell–cell
adhesion molecules, which are essential for the induction and
maintenance of tissue structures (Takeichi, 1991; Nagar et al, 1996)
E-cadherin is present in most epithelial cells and plays an
important role in the organisation of the epithelial junctional
complex. Reduction/loss of E-cadherin has been associated with
the development and progression of human carcinomas, by
contributing to tumour invasion and metastases (Charalabopoulos
et al, 2002; Hirohashi and Kanai, 2003). Abnormal E-cadherin
expression (heterogeneous, cytoplasmic, or absent) has been
detected immunohistochemically in a variety of poorly differ-
entiated, invasive and metastatic carcinomas, such as gastric adeno-
carcinoma, lobular breast carcinoma, colorectal tumours, prostate
adenocarcinoma, pancreatic, and bladder cancer (Charalabopoulos
et al, 2002, 2004; Chang et al, 2002; Hirohashi and Kanai, 2003;
Zhang et al, 2004; Massarelli et al, 2005). Regarding testicular
neoplasms, there are less than a handful of studies, with conflicting
results (Heidenreich et al, 1998; Saito et al, 2000; Honecker et al,
2004).
Recently, a part of our collaborative team has reported the
cloning and characterisation of dysadherin (HSPCii3, IWU-1,
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sKCT1, PIC), a cell membrane glycoprotein, which has an anticell–
cell adhesion function and downregulates E-cadherin, in a post-
transcriptional manner (Ino et al, 2002; Tsuiji et al, 2003). So far
reports on the function and expression of dysadherin in tumour
samples are limited. This novel cancer-associated protein has been
detected in gastric, colorectal, pancreatic, esophageal, thyroid
tongue, and cervical carcinomas as well as in malignant melanoma
and associated with tumour aggressiveness (Aoki et al, 2003; Sato
et al, 2003; Shimamura et al, 2003, 2004; Nakanishi et al, 2004;
Shimada et al, 2004a,b; Wu et al, 2004; Nishizawa et al, 2005).
There are no reports on the expression of dysadherin in testicular
neoplasms.
The aim of the present study was to examine the expression of
dysadherin in testicular GCTs and testicular lymphomas, to
associate it with the expression of E-cadherin; and to investigate
whether there is correlation with venous/lymphatic invasion.
MATERIALS AND METHODS
In all, 120 formalin-fixed, paraffin-embedded archival tissue blocks
of testicular neoplasms were included in the current study. The
material consisted of 37 seminomas (26 classic, five spermatocytic,
and six anaplastic), 45 embryonal carcinomas, 10 mixed germ cell
tumours, two yolk sac tumours, 10 mature, and eight immature
teratomas and eight non-Hodgkin B-cell lymphomas. They
corresponded to an equal number of patients (mean age 32.9
years, range 17–78) with clinical stage I testicular neoplasms, as
defined by negative radiographic findings of chest, abdomen, and
pelvis as well as decrease of the relevant tumour markers after
radical orchiectomy (Heidenreich et al, 1998). In seven seminomas
and nine embryonal carcinomas preinvasive CIS/ITGCNU was
noted at the periphery of the invasive tumour. The most
representative block from each tumour and in cases of mixed
tumours, the block containing all cell types was selected. A section
from each block was stained with Haematoxylin and Eosin and
examined by two experienced pathologists (AB and CS) for vascular
invasion. Lymphatic invasion was recognised when tumour cells
either adhered to a vessel wall of usually irregular shape or filled a
space lined by endothelial cells without red blood cells, while
venous invasion was noted when the vessel wall was thicker and the
space contained red blood cells. For statistical purposes both
lymphatic and venous invasion were recorded as vascular invasion
(VI), as previously reported (Heidenreich et al, 1998).
Immunohistochemistry
We performed immunostaining on formalin-fixed, paraffin-
embedded tissue sections using the EnVision System (DAKO),
and the monoclonal antibodies: NCC-M53 against dysadherin and
E-cadherin (CM170B, Biocare Medical). Briefly, 4mm-thick tissue
sections were deparaffinised in xylene; rehydrated through graded
concentrations of alcohol and heated in a microwave oven for two
cycles of 15min each at 300W, in citrate buffer, for antigen
retrieval. Endogenous peroxidase activity was blocked with H2O2
solution in methanol (0.01 M), for 30min. After washing with PBS
for 5min, the primary antibodies NCC-M53 (dilution 1:1000) and
CM170B (dilution 1:50) were applied for incubation (30min at
room temperature and overnight at 41C, respectively). Then the
slides were washed for 10min with PBS and were visualised with
the EnVision system using diaminobezidine tetrahydrochloride as
a chromogen. Finally, all sections were counterstained with
haematoxylin.
Evaluation of the staining
Two pathologists (AB and CS) without knowledge of the clinical
data performed independently semiquantitative evaluation of the
staining. There was a high level of conformity, 98.3% for
dysadherin and 97.5% for E-cadherin. Where disagreement arose,
slides were reviewed together and a consensus view was obtained.
For each sample, at least 1000 neoplastic cells were counted, and
the percentage of the cancer cells with positive membranous
immunostaining as well as the staining intensity were recorded.
Staining for both antibodies was graded as 0, if no cells were
stained, 1þ if 1–25% of cells were stained, 2þ if 26–49% of cells
were stained, 3þ if 50–74% of cells were stained, and 4þ if
475% of cells were stained. For the purposes of statistical analysis,
samples that showed weak intensity and/or low frequency of
expression (o50%) were grouped together as ‘Low dysadherin or
‘Low E-cadherin’, as previously described (Aoki et al, 2003).
Staining for E-cadherin was more heterogeneous, since in many
cases only granular cytoplasmic staining was noted, while in others
a weak incomplete membranous staining was observed. Such
staining patterns were considered aberrant.
Statistical analysis
Analyses were conducted in SPSS software version 11.0 (SPSS Inc.,
Chicago, IL, USA). For comparisons between antibodies’ expres-
sion with clinicopathological variables, we used the chi-square (w
2)
test. All differences were considered statistically significant if
Po0.05. P-values are two-tailed.
RESULTS
Dysadherin expression
Dysadherin immunostaining was mostly observed in the mem-
branes of the neoplastic cells and it was homogenous throughout
the neoplasm (Figure 1). No dysadherin expression was detectable
in adjacent non-neoplastic testis, in any stage of spermatogenesis,
or in CIS/ITGCNU. Positive staining of lymphocytes and
endothelial cells was used as an internal positive control.
Dysadherin was highly expressed in the majority of seminomas,
in all yolk sac tumours and embryonal carcinomas, as well as in the
epithelial component of mature teratomas (Figure 1A–C). In
immature teratomas glandular formations were stained for
dysadherin, but not the hypercellular immature stroma or the
neuroepithelium (Table 1). In mixed GCT each component
retained the expression characteristics consistent with its micro-
scopic appearance (Table 1). Interestingly, in all lymphomas
dyasdherin was highly expressed (Figure 1D).
In 10 of the embryonal carcinomas, vascular invasion was noted
at the periphery of tumour. These neoplastic emboli also stained
positively for dysadherin, in a manner similar to the primary
tumour (Figure 1E).
High dysadherin expression was correlated with specific
histologic types (w
2, Po0.05), but not with higher incidence of
vascular invasion.
E-cadherin expression
Non-neoplastic germ cells, Sertoli cells, and interstitial cells were
all negative for E-cadherin. However, the majority of the tumours
showed an heterogeneous intratumoral expression pattern
(Figure 2). E-cadherin was not expressed in spermatocytic
seminomas (complete absence of staining), while it was aberrantly
expressed in 19% of classic seminomas (incomplete membranous
staining in 450% of neoplastic cells) and in the majority of
anaplastic seminomas (67%) (Figure 2A, Table 1). In the majority
of embryonal carcinomas (84%) there was some staining for
E-cadherin. Specifically, aberrant cytoplasmic expression of E-
cadherin was detected in most of them (67%), while membranous
expression in 450% of neoplastic cells was noted in only eight
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sFigure 1 High membranous dysadherin expression in (A) classic seminoma, (B) embryonal carcinoma, (C) epithelial component of mature teratoma,
(D) non-Hodgkin B-cell lymphoma, and (E) neoplastic embolus of embryonal carcinoma.
Table 1 Results of immunostaining, differentiated by histological subtype
Dysadherin E-Cadherin
Histology No cases High Low High Low Aberrant
CIS/ITGCNU 16 0 16 (100%) 0 16 (100%) 0
Seminoma (SE)
Classic 26 17 (65%) 9 (35%) 0 21 (81%) 5 (19%)
Spermatocytic 5 5 (100%) 0 0 5 (100%) 0
Anaplastic 6 6 (100%) 0 0 2 (33%) 4 (67%)
Yolk sac tumour 2 2 (100%) 0 0 0 2 (100%)
Teratoma (epithelial comp.)
Mature 10 10 (100%) 0 0 0 10 (100%)
Immature 8 8 (100%) 0 0 8 (100%) 0
Embryonal Carcinoma (EC) 45 45 (100%) 0 8 (17%) 7 (16%) 30 (67%)
Mixed Germ Cell tumour 10
EC component 10 10 (100%) 0 2 (20%) 2 (20%) 6 (60%)
SE component 10 6 (60%) 4 (40%) 0 9 (90%) 1 (10%)
Lymphoma 8 8 (100%) 0 0 8 (100%) 0
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scases (17%) (Figure 2B and C, Table 1). In mixed GCT each
component retained the expression characteristics consistent
with its microscopic appearance (Table 1). Both yolk sac tumours
examined demonstrated aberrant (cytoplasmic) E-cadherin ex-
pression. In the epithelial component of mature teratomas
aberrant (cytoplasmic) staining for E-cadherin was noted
(Figure 2D). In immature teratomas glandular formations were
negative for E-cadherin, as well as all other immature tissues
recognised. As expected all lymphomas were completely negative
for E-cadherin.
Of all the tumours examined colocalisation of dysadherin and
membranous E-cadherin staining in 450% of neoplastic cells was
noted only in 17% of embryonal carcinomas (judged by comparing
tumour areas in adjacent slides). In all other cases, where E-
cadherin staining was noted, intense membranous staining for
dysadherin was associated with weak/moderate granular cytoplas-
mic (aberrant) staining for E-cadherin. There was no tumour with
high expression of E-cadherin and low expression of dysadherin.
There was a reverse association between increased dysadherin
expression and decreased/aberrant E-cadherin expression (w
2,
Po0.05).
We did not observe a significant association between decreased
E-cadherin expression and higher incidence of vascular invasion
(w
2 P40.05). In all 10 cases of embryonal carcinomas where
vascular invasion was noted, the neoplastic emboli exhibited
E-cadherin staining comparable to that of the primary tumour
(Figure 2E).
DISCUSSION
Since the frequency of testicular neoplasms, which affect primarily
young males, has increased in developed countries the search
for new molecules possibly involved in their pathogenesis and
progression is of high importance (Heidenreich et al, 1998;
Delgado et al, 2000; Aubry et al, 2001). Embryonal carcinoma
is composed of primitive carcinoma-like cells with minimal or
no signs of differentiation. In teratomas the differentiation is
towards structures of the embryo proper, usually a combination
of endodermic, mesodermic, and ectodermic tissues. Yolk sac
tumours are directed towards the formation of extraembryonic
endoderm, and mesoderm. Traditionally seminomas have been
regarded as ‘end point’ neoplasms incapable of further differentia-
tion in any of the directions of the NSGCTs. However, the presence
of anaplastic seminoma is an indicator that there exists a testicular
tumour situated between classic seminoma and embryonal
carcinoma, and may represent the link between them (Mostofi
and Sobin, 1997; Rosai, 2004).
Figure 2 Aberrant E-cadherin expression in (A) classic seminoma, (C) embryonal carcinoma, (D) epithelial component of mature teratoma, and (E)
neoplastic embolus of embryonal carcinoma. (B) High membranous E-cadherin expression at the cell–cell borders of neoplastic embryonal carcinoma cells.
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sIn our study, the expression of dysadherin appears to be high
in all types of germ cell tumours, which demonstrate either
embryonic phenotype or somatic differentiation as well as in most
terminally differentiated neoplasms, that is seminomas. Since
dysadherin is not normally expressed in non-neoplastic germ cells,
it is conceivable that it is a molecule that plays a pivotal role in
the neoplastic transformation of germ cells. Furthermore, it is
intriguing that dysadherin in not expressed in CIS/ITGCNU,
suggesting that it is a key protein involved in the acquirement of
the invasive phenotype, both on seminomas and in NSGCTs.
However, dysadherin expression did not correlate with vascular
invasion. Since this is the first study on dysadherin expression in
testicular neoplasms, it is too early to speculate about the role of
this protein in the pathogenesis of these tumours. This is also the
first report on dysadherin expression in lymphomas. The latter is
not surprising, given that dysadherin is normally expressed in
lymphocytes and the fact that lymphomas are well known for the
lack of cohesiveness between neoplastic cells. Further studies in
lymphomas developing in lymph nodes are needed in order to
further examine the role of dysadherin in this large category of
neoplasms.
Until now, dysadherin expression has been studied in colorectal,
pancreatic, gastric, esophageal, tongue and thyroid carcinomas, as
well as in cervical squamous cell carcinomas and cutaneous
malignant melanomas (Aoki et al, 2003; Sato et al, 2003;
Shimamura et al, 2003, 2004; Nakanishi et al, 2004; Shimada
et al, 2004a,b; Wu et al, 2004; Nishizawa et al, 2005). In all these
cancer types, a general phenomenon is that dysadherin expression
seems to reflect tumour aggressiveness, being furthermore a
marker of poor prognosis when considered alone or/and in
combination with downregulation of E-cadherin. A process
involving increased dysadherin expression may lead to an adverse
clinical outcome.
Our results also expand the published information on E-
cadherin expression in testicular tumours. Heidenreich et al (1998)
reported E-cadherin expression in 76.1% of NSGCTs, as well as
positive staining in benign testicular tissue. The latter is not
confirmed by our study, neither by that of Saito et al (2000), who
showed that E-cadherin was not expressed in normal germ cells.
They further demonstrated that E-cadherin was expressed in 18.8%
of seminomas and 62.5% of NSGCTs, mainly on the epithelial
component of teratoma cells. Honecker et al (2004) demonstrated
that E-cadherin was not expressed in CIS/ITGCNU, in seminomas
and dysgerminomas, while it was found in the majority of
NSGCTs. Our results are in accordance with these studies if we
take in account the functional membranous as well as the aberrant
cytoplasmic E-cadherin immunostaining. It is not possible to
further compare our data with the above-mentioned studies, since
a detailed analysis of E-cadherin expression is not provided, and
none of the figures shows E-cadherin immunostaining in
seminomas or embryonal carcinomas. Nonetheless, it appears that
E-cadherin protein is synthesised by the neoplastic cells, but
probably not directed properly to the cell membrane, in most
cases. A corollary to this hypothesis is the information provided by
Kawakami et al (2003) who using multipoint methylation analysis
have not detected methylation in E-cadherin neither in seminomas
nor in NSGCTs, but have shown a consistent aberrant E-cadherin
methylation in testicular lymphomas . In agreement with this,
none of our eight non-Hodgkin B-cell lymphomas showed any
expression of E-cadherin. As reported previously, E-cadherin
expression did not correlate with vascular invasion (Heidenreich
et al, 1998).
Regarding seminomas the differential expression of dysadherin
and E-cadherin possibly reflects the unique aspects of their
pathobiology. Interestingly, spermatocytic seminoma, which is
regarded as a low-grade malignancy, showed increased expression
of dysadherin and absent E-cadherin, while anaplastic tumours,
that have more aggressive behaviour exhibited concomitant high
expression of dysadherin and aberrant E-cadherin, similar to that
observed in embryonal carcinomas. In classic seminomas the
expression of the two molecules is somewhere in between. These
findings lend further support to the hypothesis that anaplastic
seminomas are the link between seminomas and embryonal
carcinomas.
Increased dysadherin expression was correlated with aberrant
E-cadherin expression. E-cadherin is produced by ribosomes on
the endoplasmic reticulum, as a precursor molecule which is
cleaved at preregion, forming a mature molecule of 120kDa that
migrates intracellularly, taking finally a place in the cytoplasmic
membrane and acquiring a functional extracellular carboxy
domain. Thus, cytoplasmic distribution of E-cadherin represents
an aberrant expression pattern, since in this location E-cadherin is
not able to mediate cell–cell adhesion interactions.
As was mentioned herein, colocalisation of dysadherin and
membranous (normal/functional) E-cadherin staining in more
than 50% of neoplastic cells was noted only in 17% of embryonal
carcinomas. This finding suggests that other mechanisms apart
from dysadherin regulation are implicated in E-cadherin expres-
sion/activity both at transcriptional and post-transcriptional
level. Dysadherin may only partly suppress/regulate the activity
of E-cadherin. Many other factors may also be involved, such as
methylation of the promoter region, gene mutation, involvement
of snail, sip-1, and slug transcription factors, ubiquination of E-
cadherin, tyrosine phosphorylation of a ˆ-catenin, as well as catenin
abnormalities, such as absence of a-catenin. In addition, there
may be a threshold level of dysadherin for downregulation of
E-cadherin, and downregulation of E-cadherin expression is not
the only mechanism by which dysadherin affects the aggressive-
ness of embryonal testicular tumours.
In conclusion, this is the first report on dysadherin expression
and its association with E-cadherin in testicular tumours.
Expression patterns in all histological types were described and
their possible implication in neoplastic transformation have been
discussed. Larger prospective studies, fulfilling many clinicopatho-
logical parameters are needed in order to clarify the important
issue of testicular carcinogenesis.
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